Sign in
DRMAW Stock Price, Chart, Stats & News
Dermata Therapeutics, Inc.
Save
Dermata Therapeutics, Inc. (DRMAW) does not currently pay a dividend.
409
Market cap
–
Current P/E
–
Forward P/E
DRMAW chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -96.12% |
ROE | -130.89% |
D/E | – |
Interest coverage ratio | – |
DRMAW valuation
P/E | – |
P/S | – |
P/B | 0.23x |
P/CF | -0.19x |
P/FCF | -0.10x |
P/OCF | -0.19x |
PEG | -0.00x |
EV multiple | -1.10x |
About
Dermata Therapeutics, Inc., a biotechnology company in the clinical development stage, is headquartered in San Diego, California, and was established in 2014. The firm's core mission is to develop innovative treatments for a variety of dermatological and cosmetic skin conditions. Its flagship investigational product, DMT310, is a topical formula applied once weekly that is currently undergoing clinical trials.
Similar securities
Based on sector and market capitalization
Report issue